Buspirone in the Treatment of 2-6 Year Old Children With Autistic Disorder

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2009
The purpose of this study is to evaluate the effects of twice-daily oral buspirone on core features of autism in autistic children aged 2-6 years as measured by the change from baseline in the Autism Diagnostic Observation Schedule (ADOS) Composite Total scores compared to placebo at 6 months.
Epistemonikos ID: 82f2fd43b702822cf34f6a9974d16cb593e5ae93
First added on: May 05, 2024